Accentia Biopharmaceuticals (ABPI) Reports Q3 Loss of $0.25
More News related to ABPI
- Accentia Biopharmaceuticals (ABPI) Reports Q3 Loss of $0.25
- Accentia Biopharmaceuticals (ABPI) Agrees to $8.5M Private Placement to Fund SinuNase(TM) and Revimmune(TM) Strategies
- Unusual 11 Mid-Day Movers 6/11: ABPI, KMGB, FCN, AGU Higher; CENT, FED, SNIC, MTG Lower
- Accentia Biopharmaceuticals (ABPI) Announces SinuNase Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant
- Pre-Open Movers 4/17: FUQI Intl (FUQI) Higher on Raised Guidance, Nokia (NOK) Lower on Results/Outlook
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) reports a Q3 loss of $0.25, which includes $0.08 attributable to Biovest, which does not compare to the analyst estimate of $0.03.
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
